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National University Hospital, Copenhagen, DenmarkAbstractWe ﬁrst describe two novel variants of blaKPC, blaKPC-16 and
blaKPC-17, which were identiﬁed in three Klebsiella pneumoniae
isolates from a patient in Taiwan. KPC-16 and KPC-17 differed
from KPC-2 by two (P202S and F207L) and a single (F207L) amino
acid substitutions, respectively. All three isolates with identical
pulsotype belonged to sequence type 11. The MICs of the three
isolates for colistin and tigecycline were 0.5 μg/mL and 2 μg/mL,
respectively. Moreover, an outbreak of at least 39 blaKPC-17-
containing K. pneumoniae isolates is ongoing in southern Taiwan in
2014. Physicians should know that blaKPC-17-containing isolates can
substantially threaten public health.
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β-lactamases and increased carbapenem use may escalate the
occurrence of carbapenem-resistant Enterobacteriaceae [1].
Klebsiella pneumoniae carbapenemase (KPC) is one of the most
common carbapenemases, and KPC-2-containing K. pneumoniae
(KPC-2-KP) strains with sequence type (ST) 258 and ST 11
clones have been the most widespread [2–4].
In Taiwan, KPC-2-KP was ﬁrst recovered in 2010 from a
returning businessman in northern Taiwan who had acquired
pneumonia in China [5]. The second report was an intra-hospital
spread of ST 11 KPC-2-KP between two patients in central
Taiwan in 2010 [6]. In 2011, 16 KPC-2-KP isolates (ST 11 clone)
disseminated among four hospitals in northern Taiwan [7]. In
2012, nationwide surveillance identiﬁed 41 KPC-2-KP isolates
[8]. Among them, a KPC-2-KP strain was recovered from a
patient hospitalized at the Chi Mei Medical Centre (CMMC) in
southern Taiwan. The patient had repeated sputum isolates of
imipenem-resistant K. pneumoniae, and two novel blaKPC vari-
ants, blaKPC-17 and blaKPC-16, were identiﬁed in the current study.
Later, in 2014, an outbreak of blaKPC-17-containing
K. pneumoniae (KPC-17-KP) occurred in another regional hos-
pital, which was located in a different district within the same city
as CMMC. So far, at least 39 KPC-17-KP isolates (19 urinary
isolates, 17 sputum isolates and three blood isolates) have been
recovered from 38 patients, causing 33.3% mortality (Fig. 1).
Among them, 23 isolates were nosocomial, 12 were acquired
from seven long-term care facilities and four were community-
acquired. The outbreak is still ongoing and KPC-17-KP is
posing a serious threat to public health.We aimed to describe the
two novel KPC variants.
A 70-year-old man was admitted to CMMC with recurrent
haemangioblastoma. After resection of the tumour, imipenem
was initiated for extended-spectrum β-lactamase-KP pneumonia
since 24 July 2012. However, the sputum culture obtained on 20
August yielded an imipenem-resistant K. pneumoniae (designated
CRE-043). Therefore, imipenem was replaced by tigecycline and
fosfomycin. Two imipenem-resistant K. pneumoniae sputum iso-
lates (MDRKP-209 andMDRKP-288)were still recovered. As the
pneumonia became stationary, the patient was discharged un-
eventfully. The institutional review board (IRB) of CMMC had
evaluated and approved the study (IRB10012-001). The three
imipenem-resistant K. pneumoniae isolates were investigated;
they were resistant to cefazolin, cefuroxime, ceftazidime, cef-
triaxone, ﬂomoxef, piperacillin-tazobactam and ciproﬂoxacin,
but were susceptible to gentamicin and amikacin by Bauer-Kirby
disk diffusion test. The MIC dilution method demonstrated that
colistin, amikacin, gentamicin and trimethoprim/sulfamethoxa-
zole were the most active agents against the three isolates and
tigecycline activity was intermediate (Table 1).Clin Microbiol Infect 2015; 21: 347.e5–347.e8
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FIG. 1. Numbers of monthly isolated carbapenem-resistant enter-
obacteriaceae (CRE) and conﬁrmed blaKPC-17-containing Klebsiella
pneumoniae (KPC-17-KP) as well as death number of the patients car-
rying the KPC-17-KP isolates from an outbreak hospital from January
through July 2014. The outbreak hospital was located at a different
district area in the same city as the Chi Mei Medical Centre in southern
Taiwan, where the KPC-17 was ﬁrst discovered in 2012.
347.e6 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIDNA of three isolates was extracted by QIAprep Spin
Miniprep kit (Qiagen, Hilden, Germany) and as templates.
Polymerase chain reaction was used to amplify class A, class B,
class C and class D β-lactamase genes by using speciﬁc primers
as previously published [1,9–11]. All amplicons were puriﬁed
for direct sequencing. KPC-2 full-length amplicons were
conﬁrmed by using cloning vector pGEM-T Easy system
(Promega, Madison, WI, USA). The sequences were analysed
with the BLAST program. Interestingly, the three isolatesTABLE 1. The microbiological and molecular characteristics of the
Characteristic/Strain CRE-043
Culture date 20 August 2012
Specimen Sputum
Previous antibiotic exposure Imipenem for 25 days
Sequence type ST 11
Pulsotype Identity
Other β-lactamase SHV-12
KPC variant KPC-17a
blaKPC location Plasmid
ompK35 vs.GU945385 1-bp FSDb
ompK36 vs. AP006725 92% Identity
MIC (mg/L) for
Amikacin <4
Gentamicin <1
Trimethoprim/sulfamethoxazole 1/19
Ciproﬂoxacin 128
Tigecycline 2
Fosfomycin 128
Colistin 0.5
Ertapenem >32
Imipenem 64
Meropenem >64
Doripenem >32
aThe isolate CRE-043 was initially identiﬁed as KPC-2-KP in a nationwide surveillance in Taiw
only the CRE-043 isolate harboured the blaKPC-17 genes (personal communications with Pro
National Health Research Institutes, Taiwan and Dr J-J Mu: Research and Diagnostic Centre
bFrame-shift deletion at position 82 downstream from the beginning nucleotide of ompK35
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcarried the blaSHV-12 gene and were positive for blaKPC genes.
DNA sequencing analysis conﬁrmed that the strains CRE-043
and MDRKP-209 carried the novel blaKPC-17 gene (GenBank
acc. No. KC465200). The strain MDRKP-288 harboured
another novel KPC variant designated blaKPC-16 (GenBank acc.
No. KC465199). KPC-17 differs from KPC-2 by a single amino
acid substitution (F207L; Ambler (ABL) numbering [12]). KPC-
16 differs from KPC-2 by two amino acid substitutions (P202S,
F207L; ABL numbering). Moreover, the KPC-17-KP ﬁrst
appeared after 25 days of imipenem therapy, but persisted and
KPC-16-KP emerged after discontinuation of imipenem ther-
apy, indicating difﬁculty in eradication of the organism and
capability of continuous evolution of a new resistant trait even
in the absence of carbapenem selective pressure.
Meanwhile, outer membrane porin-associated genes
(ompK35 and ompK36) were also screened using a PCR assay as
previously described [13]. The ompK35 genes of our three
isolates have the same mutation site as GenBank acc. no.
GU945385 strain that showed a single base frame-shift deletion
at position 82 (Table 1), which corresponded to ertapenem
resistance in an isolate collected from another hospital in
southern Taiwan [14]. Interestingly, our three ompK36 genes
are completely identical to an ompK36 mutant gene identiﬁed in
a Chinese isolate (GenBank acc. No. JX310552), which seemed
to serve as a minor cooperative factor for carbapenem resis-
tance [15].
Besides, plasmid experiments with alkaline lysis procedure
[16] and Southern blotting analysis with a digoxigenin (DIG)-
labelled probe were performed for the genetic location. The
results revealed that the blaKPC genes were located on the
plasmids and chromosomes. Moreover, blaSHV-12 gene isthree novel blaKPC-containing Klebsiella pneumoniae isolates
MDRKP-209 MDRKP-288
28 August 2012 10 September 2012
Sputum Sputum
Tigecycline and fosfomycin Tigecycline and fosfomycin
ST 11 ST 11
Identity Identity
SHV-12 SHV-12
KPC-17 KPC-16
Plasmid Plasmid
1-bp FSD 1-bp FSD
92% Identity 92% Identity
<4 <4
<1 <1
1/19 2/38
128 128
2 2
64 128
0.5 0.5
>32 >32
64 >64
>64 >64
>32 >32
an [8]. After re-sequencing analyses of the 41 KPC-2-KP isolates in that surveillance,
fessor L. Kristopher Siu: National Institute of Infectious Diseases and Vaccinology,
, Centres for Disease Control, Taiwan).
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were about 80 kb in size and were mosaic with IncFII and IncFIB
replicons. Conjugation experiments were performed by the
ﬁlter mating method [17] and a sodium-azide-resistant strain
Escherichia coli J53 was used as the recipient strain. However,
repeated conjugation for these strains failed to transfer the
imipenem resistance trait to recipient cell E. coli J53, similar to
recent reports that some KPC-producing strains failed to
transfer the blaKPC genes [18,19]. Recently, the plasmid pKPC-
LK30 carrying the blaKPC-2 gene in a Taiwanese KPC-2-KP
isolate did not harbour a conjugative transfer system, which
also failed in the conjugation experiments [20]. Pulsed-ﬁeld gel
electrophoresis [8] and multilocus sequence typing [21] were
also performed and revealed that these isolates belonged to ST
11 and had an identical pulsotype, which was similar to KPC-2-
KP isolates from northern Taiwan [8]. It should be noted that
our three isolates and the 39 KPC-17-KP outbreak isolates
were also highly similar. However, no epidemiological link with
travel from northern to southern Taiwan could be established
in the outbreak. Twenty-three (60%) cases were nosocomial
after a mean hospital stay of 12 days (range 2–47 days). Among
them, seven cases stayed in two intensive care units and 16
cases stayed in four different wards. No single unit or ward
could be regarded as an epicentre. Furthermore, 11 of the 12
patients with nursing home-acquired disease and three of the
four community-acquired patients had recent hospitalization in
the same epidemic hospital within 3 months. Seven nursing
homes were involved without signiﬁcant difference in case
distribution. The detailed epidemiological investigation and
infection controls for the ongoing outbreak are still ongoing.
In conclusion, we reported two novel KPC variants (KPC-16
and KPC-17). Colistin remained one of the most active agents
against the novel blaKPC-containing isolates. The KPC-17-KP ST
11 clone is posing an increasing challenge to physicians to
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